Completion of therapy by medicare patients with stage III colon cancer

Journal of the National Cancer Institute

Volumn 98, Issue 9, 2006, Pages 610-619

  Dobie, Sharon A ^a   Baldwin, Laura Mae ^a   Dominitz, Jason A ^b   Matthews, Barbara ^a   Billingsley, Kevin ^c   Barlow, William ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER STAGING; CLINICAL FEATURE; COLON CANCER; COLON RESECTION; COMPUTER PROGRAM; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; ENVIRONMENTAL FACTOR; FEMALE; HOSPITAL READMISSION; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; MEDICARE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHYSICAL CAPACITY; PHYSICIAN ATTITUDE; PREDICTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; RACE DIFFERENCE; RISK ASSESSMENT; SEX DIFFERENCE; SOCIAL SUPPORT; UNITED STATES; URBAN RURAL DIFFERENCE; VALIDATION PROCESS; WIDOW; ADJUVANT CHEMOTHERAPY; COLON TUMOR; FRAIL ELDERLY; PATHOLOGY; PREDICTION AND FORECASTING; REPRODUCIBILITY; RISK FACTOR; STATISTICAL MODEL; STATISTICS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; FRAIL ELDERLY; HUMANS; LOGISTIC MODELS; MALE; MEDICARE; NEOPLASM STAGING; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SEER PROGRAM; SOCIAL SUPPORT; UNITED STATES;

EID: 33646443078     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj159     Document Type: Article

References (53)

1. Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al. Surgical adjuvant therapy of large-bowel carcinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989; 7:1447-56.
2. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
3. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:1879-87.
4. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: A final report. Ann Intern Med 1995;122:321-6.
5. Wolmark N, Rockette H, Mamounas EP, Jones J, Petrelli N, Atkins J. The relative efficacy of 5-FU+leucovorin (FU-LV), 5-FU+levamisole (FU-LEV) and 5-FU+leucovorin+levamisole (FU-LV-LEV) in patients with Ducke's B and C carcinoma of the colon: First report of NSABP C-04 Proc ASCO 1996;15:205.
6. Jessup JM, McGinnis LS, Steele GD Jr, Menck HR, Winchester DP. The National Cancer Data Base. Report on colon cancer. Cancer 1996;78: 918-26.
7. NIH Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-50.
8. Ragland KE, Selvin S, Merrill DW. Black-white differences in stage-specific cancer survival: Analysis of seven selected sites. Am J Epidemiol 1991;133:672-82.
9. Hodgson DC, Fuchs CS, Ayanian JZ. Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer. J Natl Cancer Inst 2001;93:501-15.
10. Schrag D, Cramer LD, Bach FB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001;93:850-7.
11. Ayanian JZ, Zaslavsky AM, Fuchs CS, Guadagnoli E, Creech CM, Cress RD, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol 2003;21:1293-300.
12. Dominitz JA, Samsa GP, Landsman P, Provenzale D. Race, treatment, and survival among colorectal carcinoma patients in an equal-access medical system. Cancer 1998;82:2312-20.
13. Roetzheim RG, Pal N, Gonzalez EC, Ferrante JM, Van Durme DJ, Krischer JP. Effects of health insurance and race on colorectal cancer treatments and outcomes. Am J Public Health 2000;90:1746-54.
14. Tropman SE, Hatzell T, Paskett E, Ricketts T, Cooper MR, Aldrich T. Colon cancer treatment in rural North and South Carolina. Cancer Detect Prev 1999;23:428-34.
15. Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 2002;20:1192-202.
16. Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: Improved survival in stage II and III. Br J Cancer 2001;85:1437-13.
17. Potosky AL, Riley GF, Lubitz JD, Mentnech RM, Kessler LG. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 1993;31:732-48.
18. Baldwin LM, Adamache W, Klabunde CN, Kenward K, Dahlman C, Warren JL. Linking physician characteristics and Medicare claims data: Issues in data availability, quality, and measurement. Med Care 2002;40:IV-82-95.
19. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al., editors. AJCC cancer staging manual. 6th ed. New York (NY): Springer; 2002.
20. O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr, Erlichman C, Shepherd L, et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16:295-300.
21. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 1993;46:1075-9; discussion 81-90.
22. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40:373-83.
23. Morrill R, Cromartie J, Hart LG. Metropolitan, urban, and rural commuting areas: Toward a better depiction of the US settlement system. Urban Geogr 1999;20:727-48.
24. WWAMI Rural Health Research Center. Rural-urban commuting area codes (RUCAs). Available at: http://www.fammed.washington.edu/wwamirhrc/. [Last accessed: December 13, 2004.]
25. Schrag D, Cramer LD, Bach PB, Cohen AM, Warren JL, Begg CB. Influence of hospital procedure volume on outcomes following surgery for colon cancer. JAMA 2000;284:3028-35.
26. Schrag D, Panageas KS, Riedel E, Cramer LD, Guillem JG, Bach PB, et al. Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg 2002;236:583-92.
27. Schrag D, Panageas KS, Riedel E, Hsieh L, Bach PB, Guillem JG, et al. Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J Surg Oncol 2003;83:68-79.
28. Warren JL, Harlan LC, Fahey A, Virnig BA, Freeman JL, Klabunde CN, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002;40:IV-55-61.
29. Lamont EB, Lauderdale DS, Schilsky RL, Christakis NA. Construct validity of Medicare chemotherapy claims: The case of 5FU. Med Care 2002;40: 201-11.
30. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA 1998;280:1690-1.
31. Sloan JA, Goldberg RM, Sargent DJ, Vargas-Chanes D, Nair S, Cha SS, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002;20:1491-8.
32. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11-7.
33. Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer 1998;34:1871-5.
34. Chansky K, Benedetti J, Macdonald JS. Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma. Cancer 2005;103:1165-71.
35. Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999;17:2412-8.
36. Bower M, Asbury R, Kramer Z, Pandya K, Bennett JM. Adjuvant chemotherapy for colorectal cancer in the elderly: Population-based experience. Proc ASCO 1993;12:195 (Abs #570).
37. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998;16:3537-41.
38. Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001;345:1091-7.
39. Steinberg J, Erlichman C, Gadalla T, Fine S, Wong A. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer 1992;28A:1817-20.
40. Chiara S, Nobile MT, Vincenti M, Lionetto R, Gozza A, Barzacchi MC, et al. Advanced colorectal cancer in the elderly: Results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol 1998;42:336-40.
41. Aschele C, Guglielmi A, Tixi LM, Bolli E, Mori AM, Lionetto R, et al. Adjuvant treatment of colorectal cancer in the elderly. Cancer Control 1995;2:36-8.
42. Begg CB, Carbone PP. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 1983;52:1986-92.
43. Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF, Neugut AI. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002;136:349-57.
44. Iwashyna TJ, Christakis NA. Marriage, widowhood, and health-care use. Soc Sci Med 2003;57:2137-47.
45. Frey P, Stinson T, Siston A, Knight SJ, Ferdman E, Traynor A, et al. Lack of caregivers limits use of outpatient hematopoietic stem cell transplant program. Bone Marrow Transplant 2002;30:741-8.
46. Weinrich S, Coker AL, Weinrich M, Eleazer GP, Greene FL. Predictors of Pap smear screening in socioeconomically disadvantaged elderly women. J Am Geriatr Soc 1995;43:267-70.
47. Turner MJ, Killian TS, Cain R. Life course transitions and depressive symptoms among women in midlife. Int J Aging Hum Dev 2004;58: 241-65.
48. Robertson R, Campbell NC, Smith S, Donnan PT, Sullivan F, Duffy R, et al. Factors influencing time from presentation to treatment of colorectal and breast cancer in urban and rural areas. Br J Cancer 2004;90:1479-85.
49. Colleoni M, Mandala M, Peruzzotti G, Robertson C, Bredart A, Goldhirsch A. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet 2000;356:1326-7.
50. McCollum AD, Catalano PJ, Haller DG, Mayer RJ, Macdonald JS, Benson AB 3rd, et al. Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst 2002;94:1160-7.
51. Zippin C, Lum D. Study of completeness of the surveillance, epidemiology and end results SEER program case ascertainment by hospital size and casefinding source. Health Rep 1993;5:87-90.
52. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 2002;40:IV-3-18.
53. Nattinger AB, McAuliffe TL, Schapira MM. Generalizability of the surveillance, epidemiology, and end results registry population: Factors relevant to epidemiologic and health care research. J Clin Epidemiol 1997;50:939-45.